REVENUE (Tables)

9 Months Ended

Sep. 30, 2019

Revenue from Contract with Customer [Abstract]

Schedule of revenue from contracts with customers

The following table summarizes revenue from contracts with customers for the three and nine months ended September 30, 2019 and 2018 (in thousands):

	Three Months Ended September 30,						Nine Months Ended September 30,
	2019			2018			2019			2018
Product sales, net
Gralise	$	14,931		$	14,630		$	46,008		$	43,272
CAMBIA	8,135			10,365			23,701			24,870
Zipsor	3,273			4,441			9,028			13,175
Total neurology product sales, net	26,339			29,436			78,737			81,317
NUCYNTA products	1,254			11			1,153			18,782
Lazanda	(91		)	(12		)	(1		)	528
Total product sales, net	27,502			29,435			79,889			100,627
Commercialization agreement:
Commercialization rights and facilitation services, net	27,304			27,781			89,163			87,055
Revenue from transfer of inventory	—			—			—			55,705
Royalties and milestone revenue	341			20,277			1,226			25,784
Total revenues	$	55,147		$	77,493		$	170,278		$	269,171

Summary of contract assets and liabilities

The following table presents changes in the Company’s contract assets as of September 30, 2019 (in thousands):

	Balance as of							Balance as of
	December 31, 2018		Additions		Deductions			September 30, 2019
Contract assets:
Contract asset - CAMBIA Canada	$	—	$	300	$	—		$	300
Contract asset - Collegium, net	2,416		579		(1,024		)	1,971
	$	2,416	$	879	$	(1,024	)	$	2,271